phase i/ii study of ms-553, a selective pkc-ß inhibitor, in patients with cll and sll
Published 1 year ago • 85 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
0:59
initial results with the use of ms-553 in patients with cll/sll
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
1:04
a phase i/ii study evaluating ms-553 in patients with cll/sll
-
9:09
calculating yields of monochlorination products- dr. tania cs
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
2:18
diagnosis monoclonal b cell lymphocytosis
-
8:02
cervical spondylotic myelopathy❗spinal cord compression
-
3:33
tg-1701: monotherapy & combination with u2 for cll and lymphoma
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
2:55
umbralisib for cll patients intolerant to btk inhibitors
-
1:33
btki inhibitors in the treatment of b-cell lymphoma - introduction
-
1:32
novel treatment combinations for flt3-mutated aml
-
1:32
selecting btk inhibitors for patients with mcl
-
3:40
pi3k inhibitors for cll
-
1:30
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
1:29
blinatumomab in combination with checkpoint inhibitors for all
-
1:10
nemtabrutinib (arq 531) in covalent btki resistant cll
-
1:40
sf3b1 as therapeutic target in flt3/itd positive aml
-
2:48
btk inhibitors in the treatment of dlbcl: trials investigating these agents